Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of small molecule drugs, primarily focusing on virology and immunology indications. Founded in 1995 and headquartered in Watertown, Massachusetts, the company's mission is to leverage its expertise in medicinal chemistry, molecular biology, and pharmacology to discover and develop groundbreaking, best-in-class oral therapies that profoundly improve patients' lives, with a clear vision to deliver curative treatments.

Enanta has a notable history of success, having collaborated with AbbVie to discover two protease inhibitor compounds, glecaprevir and paritaprevir. These compounds are integral to combination regimens, such as MAVYRET® and VIEKIRA PAK®, which have been instrumental in curing over one million people with chronic hepatitis C virus (HCV) infection. Currently, Enanta's clinical programs are concentrated on respiratory syncytial virus (RSV), with candidates like zelicapavir and EDP-323, and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting mechanisms such as KIT, STAT6, and MRGPRX2 inhibition, including EDP-978. The company also maintains development programs for Hepatitis B virus (HBV) with EDP-514 and human coronaviruses/SARS-CoV-2 with EDP-235.

Led by President and CEO Jay R. Luly, Ph.D., Enanta Pharmaceuticals continues to advance its pipeline. Recent activities include the dosing of the first participant in a Phase 1 clinical trial for EDP-978, an oral KIT inhibitor for urticaria, announced in April 2026. The company is also scheduled to present data for zelicapavir, an RSV treatment, at ESCMID Global 2026, and for its STAT6 Inhibitor Program at IMMUNOLOGY2026™ in March and April 2026, respectively. Enanta's stock, traded on NASDAQ under the ticker ENTA, saw activity in late April 2026, and analysts like Jefferies reiterated a Buy rating with a $20.00 price target in March 2026, reflecting its ongoing efforts in addressing high unmet medical needs through innovative drug discovery.